HAVANA, Cuba, September 3 (ACN) As part of his current official visit to China, Cuban President Miguel Díaz-Canel visited the joint venture Biotech Pharmaceuticals Limited (BPL), established within the framework of bilateral collaboration in the field of biotechnology and described by the Cuban leader as a mature, stable and ever-innovating entity deemed a benchmark in China and a source of pride for Cuba.
In a post on X, the Cuban Presidency remarked that BPL's core activity is related to the use of Cuban technology in the manufacture and sale of biotech products in China―where they have been supplied to some 2,000 hospitals―as well as to the development of new products.
The message points out that BPL is a model of cooperation which has made tangible contributions to the health of both peoples and a production platform abroad for the provision of biotechnology products to Cuba.
BPL's current leading product is Nimotuzumab, a Cuban monoclonal antibody used in cancer treatment that inhibits the uncontrolled proliferation of malignant cells, whereas the process to produce Cimavax, a therapeutic vaccine against the most prevalent lung cancer in the world, is currently being transferred.
According to BioCubaFarma president Mayda Mauri, the primary beneficiaries of these products are the Cuban and the Chinese people.
On his end, Díaz-Canel emphasized the need to increase export volumes to China, Cuba, and the competitive and demanding Association of Southeast Asian Nations (ASEAN) market.
Díaz-Canel visits Chinese-Cuban biotechnology company
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio